Skip to main content
Log in

Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The neuronal mechanisms of neurotensin (NT)-induced catalepsy were investigated in mice. NT administered intracerebroventricularly (ICV 0.5, 1.0 and 2.0 μg) produced catalepsy in a dose-dependent fashion. A significant effect was observed at 2.0 μg and a maximal effect 2–3 h after injection. The NT-induced catalepsy was inhibited by pretreatment with atropine, trihexyphenidyl or biperiden (each drug, 0.8–5.0 mg/kg, IP), anticholinergic drugs, and L-DOPA (100, 200 mg/kg, IP). However, the catalepsy was not significantly antagonized by p-chlorphenylalanine (300 mg/kg×3 days, IP) or methysergide (5, 10 mg/kg, IP), antiserotonergic drugs, and was not potentiated by the GABAergic drugs, aminooxyacetic acid (25 mg/kg, IP) or muscimol (1 mg/kg, IP). In addition, the NT-induced catalepsy was dose-dependently reduced by antihistamines, such as diphenhydramine (0.8–10 mg/kg, IP) and tripelennamine (0.4–5.0 mg/kg, IP) and was potentiated after treatment with histidine (250, 500 mg/kg, IP), a precursor of brain histamine. NT-induced catalepsy was also reduced by ICV pretreatment with diphenhydramine (1–5 μg/rat), a H1 antagonist, but not by cimetidine (5, 20 μg/rat), a H2 antagonist. These findings suggest that the catalepsy induced by NT may involve not only central cholinergic and dopaminergic mechanisms but also a histaminergic mechanism mediated via H1-histamine receptors, and seems to differ from the catalepsy induced by neuroleptics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andén NE (1974) Inhibition of the turnover of the brain dopamine after treatment with gamma-aminobutyrate: 2-oxyglutarate transaminase inhibitor aminooxyacetic acid. Naunyn-Schmiedebergs Arch Pharmacol 283:419–424

    Google Scholar 

  • Biswas B, Carlsson R (1977) The effects of intracerebroventricularly administered GABA on brain monoamine metabolism. Naunyn-Schmiedebergs Arch Pharmacol 299:41–46

    Google Scholar 

  • Bowers MB Jr, Roth RH (1972) Interaction of atropine-like drugs with dopamine-containing neurones in rat brain. Br J Pharmacol 44:301–306

    Google Scholar 

  • Brown J, Handley SL (1980) The development of catalepsy in drug-free mice on repeated testing. Neuropharmacology 19:675–678

    Google Scholar 

  • Carraway R, Leeman SE (1973) The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 248:6854–6861

    Google Scholar 

  • Carraway R, Leeman SE (1976) Radioimmunoassay for neurotensin, a hypothalamic peptide. J Biol Chem 251:7035–7044

    Google Scholar 

  • Checler F, Vincent JP, Kitabgi P (1983) Neurotensin analogs [D-TYR11] and [D-PHE11] neurotensin resist degradation by brain peptidases in vitro and in vivo. J Pharmacol Exp Ther 227:743–748

    Google Scholar 

  • Costall B, Naylor RJ (1973) Neuroleptic and non-neuroleptic catalepsy. Arzneimittelforsch 23:674–683

    Google Scholar 

  • Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12:12–15

    Google Scholar 

  • Iversen LL, Iversen SD, Bloom F, Douglas C, Brown M, Vale W (1978) Calcium-dependent release of somatostatin and neurotensin from rat brain in vitro. Nature 273:161

    Google Scholar 

  • Jennes L, Stumpf W, Kalivas PW (1982) Neurotensin: Topographical distribution in rat brain by immunohistochemistry. J Comp Neurol 210:211–224

    Google Scholar 

  • Jolicoeur FB, Barbeau A, Rioux F, Quirion R, St-Pierre S (1981) Differential neurobehavioral effects of neurotensin and structural analogues. Peptides 2:171–175

    Google Scholar 

  • Kääriänen I (1976) Effects of aminooxyacetic acid and baclofen on the catalepsy and on the increase of mesolimbic and striatal dopamine turnover induced by haloperidol in rats. Acta Pharmacol Toxicol (Copenh) 39:393–400

    Google Scholar 

  • Kahn D, Hou-Yu A, Zimmerman EA (1982) Localization of neurotensin in the hypothalamus. Ann NY Acad Sci 400:117–131

    Google Scholar 

  • Kamei C, Dabasaki T, Tasaka K (1983) Cataleptic effect of histamine induced by intraventricular injection in mice. Jpn J Pharmacol 33:1081–1084

    Google Scholar 

  • Kameyama T, Ukai M (1983) Multi-dimensional analyses of behavior in mice treated with morphine, endorphins and (destyrosines)-gamma-endorphin. Pharmacol Biochem Behav 19:671–677

    Google Scholar 

  • Klemm WR (1985) Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology 85:139–142

    Google Scholar 

  • Kostowski W, Gumulka W, Czlonkowski A (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with parachlorophenylalanine. Brain Res 48:443–446

    Google Scholar 

  • Lazarus LH, Brown MR, Perrin MH (1977) Distribution, localization and characteristics of neurotensin binding sites in the rat brain. Neuropharmacology 16:625–629

    Google Scholar 

  • Leslie GB, Maxwell Dr (1964) Some pharmacological properties of thioproperazine and their modification by anti-parkinsonian drugs. Br J Pharmacol 22:301–317

    Google Scholar 

  • Morpurgo C, Theobald W (1964) Influence of antiparkinson drugs and amphetamine on some pharmacological effects of phenothiazine derivatives used as neuroleptics. Psychopharmacologia 6:178–191

    Google Scholar 

  • Nemeroff CB (1980) Neurotensin: Perchance an endogenous neuroleptic? Biol Psychiatry 15:283

    Google Scholar 

  • Nemeroff CB, Bissette G, Prange AJ Jr, Loosen PT, Barlow TS, Lipton MA (1977) Neurotensin: Central nervous system effects of a hypothalamic peptide. Brain Res 128:485–496

    Google Scholar 

  • Nemeroff CB, Bissette G, Manberg PJ, Osbahr AJ III, Breese GR, Prange AJ Jr (1980) Neurotensin-induced hypothermia: Evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroid axis. Brain Res 195:69–84

    Google Scholar 

  • Nemeroff CB, Luttinger D, Hernandez DE, Mailman RB, Mason GA, Davis SD, Widerlov E, Frye GD, Kilts CA, Beaumont K, Breese GR, Prange AJ Jr (1983) Interactions of neurotensin with brain dopamine systems: Biochemical and behavioral studies. J Pharmacol Exp Ther 225:337–345

    Google Scholar 

  • Nowak JZ, Pilc A, Lebrecht U, Maslinski C (1977) Does histamine interact with cholinergic neurones in its cataleptogenic action in the rat? Neuropharmacology 16:841–847

    Google Scholar 

  • Osbahr AJ III, Nemeroff CB, Manberg PJ, Prange AJ Jr (1979) Centrally administered neurotensin: Activity in the Julou-Courvoisier muscle relaxation test in mice. Eur J Pharmacol 54:299–302

    Google Scholar 

  • Sawada S, Takada S, Yamamoto C (1980) Electrical activity recorded from thin sections of bed nucleus of the stria terminalis and the effects of neurotensin. Brain Res 188:578–581

    Google Scholar 

  • Schaumann W, Kurbjuweit HG (1961) Beeinflussung verschiedener Wirkungen von Thiopropazat durch ein zentrales stimulans. Arzneimittelforsch 11:343–350

    Google Scholar 

  • Schwartz JC, Barbin C, Duchemin AM, Garbarg M, Palacios JM, Quach TT, Rose C (1980) Histamine receptors in the brain: Characterization by binding studies and biochemical effects. In: Pepeu G, Kuhar MJ, Enna SJ (ed) Receptors for neurotransmitters and peptide hormones. Raven, New York, pp 169–182

    Google Scholar 

  • Siegel S (1956) Nonparametric statistics for the behavioral sciences. The Fisher exact probability test. McGraw-Hill, New York, pp 96–104

    Google Scholar 

  • Simon P, Malatray J, Boissier JR (1970) Antagonism by amantadine of prochlorpemazine-induced catalepsy. J Pharm Pharmacol 22:546–547

    Google Scholar 

  • Snijders R, Kramarcy NR, Hurd RW, Nemeroff CB, Dunn AJ (1982) Neurotensin induces catalepsy in mice. Neuropharmacology 21:465–468

    Google Scholar 

  • Uhl GR, Snyder SH (1976) Regional and subcellular distribution of brain neurotensin. Life Sci 19:1827–1832

    Google Scholar 

  • Uhl GR, Kuhar MJ, Snyder SH (1977) Neurotensin: Immunohistochemical localization in rat central nervous system. Proc Natl Acad Sci USA 74:4059–4063

    Google Scholar 

  • Widerlov E, Kilts CD, Mailman RB, Nemeroff CB, McCown TJ, Prange AJ Jr, Breese GR (1982) Increase in dopamine metabolites in rat brain by neurotensin. J Pharmacol Exp Ther 222:1–6

    Google Scholar 

  • Worms P, Willigens MT, Lloyd KG (1978) GABA involvement in neuroleptic-induced catalepsy. J Pharm Pharmacol 30:716–718

    Google Scholar 

  • Wyngaarden JB, Seevers MH (1951) The toxic effects of antihistaminic drugs. JAMA 145:277–282

    Google Scholar 

  • Young WS III, Uhl GU, Kuhar MJ (1978) Iontophoresis of neurotensin in the area of the locus coeruleus. Brain Res 150:431–435

    Google Scholar 

  • Zetler G (1960) Pharmakologische Eigenschaften antidepressive wirkender Pharmaka. Dtsch Med Wochenschr 85:2276–2281

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shibata, K., Yamada, K. & Furukawa, T. Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice. Psychopharmacology 91, 288–292 (1987). https://doi.org/10.1007/BF00518179

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00518179

Key words

Navigation